openPR Logo
Press release

Revenue of Cholangiocarcinoma Cancer Treatment Market to Rise at 8% CAGR by 2025

09-20-2017 08:14 AM CET | Health & Medicine

Press release from: Persistence Market Research PVT. LTD.

Revenue of Cholangiocarcinoma Cancer Treatment Market to Rise

Treatment of bile duct cancer is presently achieved through combination therapies associated with chemotherapy. The study anticipates that by the end of forecast period, close to 70% of global bile duct cancer treatment revenues will be accounted by the Gemicitabine Combination Therapy.

In 2017 and beyond, more than 85% of global market value will be attributed by extrahepatic Cholangiocarcinoma as a disease indicator.

The study also observes hospital pharmacies as largest distribution channel for bile duct cancer drugs, revenues from which are expected to reach nearly US$ 250 Mn by 2025-end.

The global market for Cholangiocarcinoma treatment is also witnessing dominance from external beam radiation therapy as these services are pegged to procure more than half of market’s value through 2025.

Cholangiocarcinoma, also known as bile duct cancer, is spreading widely in Southeast Asia, particularly in the Northeast region of Thailand. High consumption of raw fish in the Asia-Pacific (APAC) region is driving the incidence of liver fluke infections, thereby stimulating the occurrence of bile duct cancer.

View and Download TOC of Cholangiocarcinoma (Bile Duct Cancer) Treatment Market Research Report@ https://www.persistencemarketresearch.com/market-research/bile-duct-cancer-treatment-market/toc

Increased industrialization is also attributing to the growth in the APAC bile duct cancer treatment market as exposure to harmful printing chemicals is high among industrial workers in countries such as China, Japan and India. Persistence Market Research’s new study on the global bile duct cancer treatment market reveals that by the end of 2025, APAC region will procure a global revenue share of over 45%.

In 2017, the global market for bile duct cancer treatments is anticipated to bring in revenues worth a little over US$ 168 Mn. Apart from rising incidence of bile duct cancer across the APAC and Middle East & Africa region, increasing healthcare spending is also expected to drive the demand for bile duct cancer treatments. Towards the end of 2025, the global bile duct cancer treatment market is projected to soar at a robust CAGR of 8%, raking in revenues worth US$ 312.3 Mn.

Request and Download Sample Report@ https://www.persistencemarketresearch.com/samples/10094

The study also reveals that ongoing trials for development of drugs on bile duct cancer treatment are creating newer pathways for improving the efficiency of treatment. Companies are exploring the clinical benefits of fusing new chemical entities in existing drugs on treatment of bile duct cancer.

The key players in global bile duct cancer treatment market are also seeking regulatory approval of combination therapies for treatment of Cholangiocarcinoma. The study has recorded such developments while profiling the market’s leading participants, which include Pfizer, Inc., F. Hoffman-La Roche AG, Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Eli Lilly and Company, Novartis AG, Sanofi, Fresenius Kabi AG, Mylan N.V., Kyowa Hakko Kirin Co Ltd., Intercept Pharmaceuticals, Inc., Accord Healthcare Inc., Delcath Systems Inc., Celgene Corporation, and Johnson & Johnson.

Buy Full Cholangiocarcinoma (Bile Duct Cancer) Treatment Market Report@ https://www.persistencemarketresearch.com/checkout/10094

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353

Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Revenue of Cholangiocarcinoma Cancer Treatment Market to Rise at 8% CAGR by 2025 here

News-ID: 727751 • Views:

More Releases from Persistence Market Research PVT. LTD.

Battery Material Market is projected to reach a valuation of US$ 110.02 billion by 2027
Battery Material Market is projected to reach a valuation of US$ 110.02 billion …
The battery material market has witnessed significant growth in recent years, driven by the increasing demand for batteries in various applications. According to recent studies, the market was valued at USD 42.1 billion in 2022 and is projected to reach USD 110.02 billion by 2027, growing at a CAGR of 14.1% during the forecast period. Click Here to Get Free Sample Copy of this Report@https://www.persistencemarketresearch.com/samples/10801 The battery material market encompasses a wide
Automated Intralogistics Material Handling Solutions Market to Hit US$ 219.3 billion by 2033
Automated Intralogistics Material Handling Solutions Market to Hit US$ 219.3 b …
Automated intralogistics material handling solution sales are anticipated to achieve a global market value of US$ 55.9 billion in 2023 and to grow steadily at a CAGR of 14.8% to reach US$ 219.3 billion by 2033. The global intralogistics material handling solutions market is experiencing a revolution with the introduction of automated systems. Automation has become a game-changer, offering greater efficiency and productivity to businesses across the globe. The market for automated intralogistics material handling solutions is projected to witness impressive growth in the coming years. Click Here to Get Free Sample Copy of this Report@https://www.persistencemarketresearch.com/samples/32829 The key drivers for the growth of the automated intralogistics material handling
Cold Chain Market is Encouraged to Reach USD 474.29 billion by 2028
Cold Chain Market is Encouraged to Reach USD 474.29 billion by 2028
The global cold chain market size was valued at USD 211.77 billion in 2020 and is expected to reach USD 474.29 billion by 2028, growing at a CAGR of 9.7% from 2021 to 2028. The growth is driven by increasing demand for perishable goods, globalization of the food trade, and technological advancements in cold chain logistics. Click Here to Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/3177 The cold chain market refers
Automated Intralogistics Material Handling Solutions Market Value to Hit US$ 219.3 Bn by 2033
Automated Intralogistics Material Handling Solutions Market Value to Hit US$ 219 …
𝐀𝐮𝐭𝐨𝐦𝐚𝐭𝐞𝐝 𝐈𝐧𝐭𝐫𝐚𝐥𝐨𝐠𝐢𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐭𝐞𝐫𝐢𝐚𝐥 𝐇𝐚𝐧𝐝𝐥𝐢𝐧𝐠 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧 𝟐𝟎𝟐𝟑, 𝐬𝐚𝐥𝐞𝐬 𝐨𝐟 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐞𝐝 𝐢𝐧𝐭𝐫𝐚𝐥𝐨𝐠𝐢𝐬𝐭𝐢𝐜𝐬 𝐦𝐚𝐭𝐞𝐫𝐢𝐚𝐥 𝐡𝐚𝐧𝐝𝐥𝐢𝐧𝐠 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐠𝐥𝐨𝐛𝐚𝐥 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒$ 𝟓𝟓.𝟗 𝐁𝐧 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐞𝐱𝐩𝐚𝐧𝐝 𝐬𝐭𝐞𝐚𝐝𝐢𝐥𝐲 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟏𝟒.𝟖% 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐚 𝐦𝐚𝐫𝐤𝐞𝐭 𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐜𝐥𝐨𝐬𝐞 𝐭𝐨 𝐔𝐒$ 𝟐𝟏𝟗.𝟑 𝐁𝐧 𝐛𝐲 𝟐𝟎𝟑𝟑. The demand in Germany is expected to increase by 15.7% CAGR from 2024 to 2033 on a value basis. U.S., China, and Germany are the leading countries in the

All 5 Releases


More Releases for Cholangiocarcinoma

Cholangiocarcinoma Therapeutics Market New Era Of Industry and Forecast 2018-202 …
Global Cholangiocarcinoma Therapeutics Market: Overview Bile duct is a system of tubes that interfaces the liver with the gall bladder. Bile duct provides a liquid called bile which is secreted in the liver and is kept in the gall bladder. The essential function of bile is breakdown of fats during processing. Cholangiocarcinoma therapeutics is ordinarily called cholangiocarcinoma. The specific reason for cholangiocarcinoma is not known. Get Exclusive PDF Sample Copy Of This
Cholangiocarcinoma Therapeutics Market Dynamic Demand by 2028
Global Cholangiocarcinoma Therapeutics Market: Overview Bile duct is a system of tubes that interfaces the liver with the gall bladder. Bile duct provides a liquid called bile which is secreted in the liver and is kept in the gall bladder. The essential function of bile is breakdown of fats during processing. Cholangiocarcinoma therapeutics is ordinarily called cholangiocarcinoma. The specific reason for cholangiocarcinoma is not known. However, some of the factors
Cholangiocarcinoma Therapeutics Market Global Industry Trend Analysis and Foreca …
Global Cholangiocarcinoma Therapeutics Market: Overview Bile duct is a system of tubes that interfaces the liver with the gall bladder. Bile duct provides a liquid called bile which is secreted in the liver and is kept in the gall bladder. The essential function of bile is breakdown of fats during processing. Cholangiocarcinoma therapeutics is ordinarily called cholangiocarcinoma. The specific reason for cholangiocarcinoma is not known. However, some of the factors
Cholangiocarcinoma Therapeutics Market - Potential Opportunities & Key players 2 …
Global Cholangiocarcinoma Therapeutics Market: Overview Bile duct is a system of tubes that interfaces the liver with the gall bladder. Bile duct provides a liquid called bile which is secreted in the liver and is kept in the gall bladder. The essential function of bile is breakdown of fats during processing. Cholangiocarcinoma therapeutics is ordinarily called cholangiocarcinoma. The specific reason for cholangiocarcinoma is not known. Order Brochure for more detailed
Cholangiocarcinoma (Bile Duct Cancer) Treatment Market worth US$ 144.2 Million
In 2017, the global market for bile duct cancer treatments is anticipated to bring in revenues worth a little over US$ 168 Mn. Apart from rising incidence of bile duct cancer across the APAC and Middle East & Africa region, increasing healthcare spending is also expected to drive the demand for bile duct cancer treatments. Towards the end of 2025, the global bile duct cancer treatment market is projected to
Yeliva receives FDA orphan drug status for cholangiocarcinoma
US Food and Drug Administration has granted orphan drug designation to Yeliva a first-in-class, orally administered, sphingosine kinase-2 selective inhibitor with anticancer and anti-inflammatory activities, for the effective treatment of cholangiocarcinoma. The drug is developed by RedHill Biopharma. The investigation suggested that the drug is well endured and can be safely administered to patients suffering from the disease. The action of mechanism for Yeliva includes circulation in the patient’s body